Showing 2441-2450 of 9822 results for "".
Revisiting Cyclosporine in the Age of Biologics: Update on Efficacy and Mechanism of Action
https://practicaldermatology.com/topics/general-topics/revisiting-cyclosporine-in-the-age-of-biologics-update-on-efficacy-and-mechanism-of-action/21937/Increased understanding of the immunologic basis of psoriasis supports the role of cyclosporine in patient management.Medical Dermatology Myths
https://practicaldermatology.com/topics/general-topics/medical-dermatology-myths/22036/Here are the facts about seven common misconceptions that may hinder effective patient care.Nonverbal Communication in the Patient Consultation
https://practicaldermatology.com/topics/practice-management/1109_07-php/22059/Recognition of the most common body language cues can help you understand what your patients may be thinking but not saying out loud.Understanding PML and Risks Associated with Biologic Therapies
https://practicaldermatology.com/topics/psoriasis/PD0509_10-php/22832/A swarm of controversy has enveloped biologics due to concerns about progressive multifocal leukoencephalopathy.The Importance and Utility of GEP Testing
https://practicaldermatology.com/series/updates-in-skin-cancer/the-importance-and-utility-of-gep-testing/35597/Hadas Skupsky, MD, a board-certified dermatologist and dermatopathologist, discusses gene expression profiling technology and its importance in the diagnosis and prognostication of melanomas.Journal Club: Biologics for Young Children
https://practicaldermatology.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-biologics-for-young-children/32400/Practical Dermatology Editorial Board member Lawrence Eichenfield, MD, FAAD, Dawn Eichenfield, MD, PhD, discuss the article "Biologic therapies in infants and children younger than 6 years of age with atopic dermatitis: suitability and practical considerations," from Expert Opinion on Drug Safety. RNoah Worcester 2024: Dr. Webster on Isotretinoin
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-webster-isotretinoin/24581/Guy Webster, MD, PhD, FAAD, summarizes his lecture on new developments in isotretinoin at the 2024 Noah Worcester Dermatological Society meeting.Noah Worcester 2024: AAD President Dr. Desai on the AAD
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-desai-aad/24589/Seemal Desai, MD, FAAD, president of the American Academy of Dermatology, summarizes his AAD update presentation at the 2024 Noah Worcester Dermatological Society meeting.James Del Rosso, DO: Thoughts on the FDA Citizen's Petition for Acne Products with Benzoyl Peroxide (BPO)
https://practicaldermatology.com/topics/acne-rosacea/james-del-rosso-do-thoughts-fda-citizens-petition-acne-products-benzoyl-peroxide-bpo/24173/James Q. Del Rosso, DO, a dermatologist and president of The American Acne and Rosacea Society (AARS), weighs in on a recent report from Valisure which finds that benzene can form at elevated levels in products for acne that contain benzoyl peroxide (BPO). The interview was conducted by Neal Bhatia,DermWireTV: Dermatologists React to the Valisure Report; FDA Approves New Treatment for Frown Lines
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-dermatologists-react-valisure-report-fda-approves-new-treatment-frown-lines/24157/In this episode of DermWireTV, dermatologists react to the recent Valisure report that found elevated levels of benzene when studied under laboratory conditions in certain acne products containing BPO; the FDA approves a new treatment option for glabellar lines; and the PA Perspectives series addres